BeneChill, Inc. started a new post-market approval study in Europe for its RhinoChill device titled PRINCE (Pre-Resuscitation Intra-Nasal Cooling Effectiveness) study. This is a randomized study to determine whether intra-nasal cooling using BeneChill’s RhinoChill device during resuscitation increases patient resuscitation and survival rates. The CE marked RhinoChill system is a non-invasive, portable, and easy-to-use device which does not use external power for rapid therapeutic patient cooling. Inert coolant is delivered to the nasal cavity using nasal catheter to reduce temperature in clinically indicated conditions. The device is easily used in emergency field settings. The study will continue till next 6-9 months in Belgium, Germany, Italy and Sweden where patients will receive either advanced cardiac life support measures (ACLS) alone or ACLS supplemented by intra-nasal cooling. “The RhinoChill Device uses the nasal cavity for cooling,” Dr. Rozenberg stressed, noting “This is advantageous since the nasal cavity allows easy access into the body, is in close proximity to the brain, and is a natural heat exchanger.”